About us

Leucid Bio is a pioneering cell therapy company with a pipeline of novel cell therapies developed using its proprietary engine. Leucid’s focus is on the development of chimeric antigen receptor T cell (CAR T) therapies for patients with solid tumours and no treatment options. The company is backed by 20 years of research history and is led by an experienced, involved management team, supported by a diverse team of passionate and committed staff.


Our Company

Leucid Bio is a clinical-stage biotech company developing cell therapies for refractory cancers, especially solid tumours. Leucid was founded to translate 20 years of King's College London (KCL) research in the CAR T field and is led by a highly experienced management team with both scientific and commercial expertise. As part of Leucid’s ongoing relationship with KCL, it benefits from exclusive access to and resources from the deep scientific, clinical and manufacturing expertise of Dr Maher and his academic team of immuno-oncology experts.

Leucid is headquartered in London, UK, with operations based at Guy’s Hospital with its own GMP manufacturing and clinical lab facilities, enabling it to maintain its patient-centric focus on developing better cell therapies for the benefit of individuals with hard-to-treat solid tumours.  

Our Mission

Our mission is to develop CAR T therapies that produce a better and more durable response than previous CAR T generations, improving treatment outcomes and saving the lives of patients with refractory cancers, most notably solid tumours.

Who We Are

Leucid is led by a committed and industry-experienced management team with deep scientific knowledge and clinical expertise in the CAR T field, and is supported by a diverse team of passionate and committed staff. Together, the Leucid team has a proven track-record in the engineering of new chimeric immune receptor systems and their translation to the clinic, maximizing the likelihood of success in safely and effectively treating hard-to-treat cancers. 

Executive Team

Artin Moussavi


Dr Artin Moussavi joined the company in May 2019 as the Chief Executive Officer. Prior to joining Leucid, Artin served as Chairman and Chief Business Officer of cell therapy company, TC Biopharm, helping to transform the business from start-up to clinical stage biopharma with over £20 million raised from equity investment and collaborations with global pharmaceutical partners. Before his roles in the cell therapy industry, Artin served as CEO of Lux Innovate applying industrial biotechnology across pharmaceutical, medical device and energy sectors. Artin founded Brathmor Ventures in 2013, investing and working with innovative companies across the biopharma, branded pharmaceuticals and nutraceutical sectors. He began his career as a research scientist at King’s College London focused on cellular immunology. Artin holds a Master of Business Administration from the University of Edinburgh Business School, a Doctorate from King’s College London and a Bachelor of Science from the University of Edinburgh.

John Maher


Dr John Maher is a clinically active consultant immunologist at Eastbourne Hospital and King’s Health Partners. While a visiting fellow in the laboratory of Michel Sadelain, he was the first to engineer and test second generation CAR technology in human T cells, building on the pioneering work of Helene Finney in the Jurkat model system. He established CAR T cell research at King’s College London in 2004 where he leads the "CAR Mechanics" group, which is focused on the development of adoptive immunotherapy using CAR engineered and gamma delta T cells. He is chief investigator of a Phase 1 clinical trial in which a pan-ErbB targeted CAR that he developed is being evaluated in patients with refractory locally advanced/ recurrent head and neck cancer.